Author information:
(1)Research Department of Oncology, UCL Cancer Institute, London, United 
Kingdom. r.kristeleit@ucl.ac.uk.
(2)Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, 
Massachusetts.
(3)Department of Medical Oncology, Sarah Cannon Research Institute, Tennessee 
Oncology, PLLC, Nashville, Tennessee.
(4)Department of Obstetrics and Gynecology, Princess Margaret Cancer Centre, 
University Health Network, Toronto, Ontario, Canada.
(5)Department of Medical Oncology, Yale University, New Haven, Connecticut.
(6)Department of Medical Oncology, Sarah Cannon Research Institute/Florida 
Cancer Specialists, Sarasota, Florida.
(7)Department of Medical Oncology, Basser Center for BRCA, University of 
Pennsylvania, Philadelphia, Pennsylvania.
(8)Department of Medical Oncology, Vall d'Hebron University Hospital and Vall 
d'Hebron Institute of Oncology, Barcelona, Spain.
(9)Department of Medical Oncology, Northern Centre for Cancer Care, Newcastle 
upon Tyne, United Kingdom.
(10)Department of Obstetrics, Gynecology, and Reproductive Sciences, Helen 
Diller Family Comprehensive Cancer Center, University of California, San 
Francisco, San Francisco, California.
(11)Department of Oncology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
(12)Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
(13)Department of Medical Oncology, Guy's Hospital, London, United Kingdom.
(14)Clinical Science, Clovis Oncology, Inc., Boulder, Colorado.
(15)Biostatistics, Clovis Oncology, Inc., Boulder, Colorado.
(16)Statistics and Data Management, Clovis Oncology, Inc., Boulder, Colorado.
(17)Clinical Pharmacology and Nonclinical DMPK, Clovis Oncology, Inc., Boulder, 
Colorado.
(18)Clinical Development, Clovis Oncology, Inc., Boulder, Colorado.
(19)Clinical and Preclinical Development, Clovis Oncology, Inc., Boulder, 
Colorado.
(20)Department of Oncology, Sheba Medical Center, Ramat Gan, Israel.